论文部分内容阅读
目的评价依折麦布对糖尿病合并高胆固醇血症患者的疗效和安全性。方法 58例临床确诊为糖尿病合并高胆固醇血症患者按随机的原则分为治疗组(依折麦布联合辛伐他汀)与对照组(常用辛伐他汀),治疗疗程均为12周,观察两组治疗前后空腹血糖、餐后2h血糖、总胆固醇、低密度脂蛋白胆固醇(LDL-C)、高敏C-反应蛋白(hs-CRP)、血肌酐(Scr)、肌酸激酶、谷丙转氨酶、谷草转氨酶。结果两组LDL-C治疗后均下降(P<0.05),且治疗组较对照组明显(P<0.01);治疗组空腹血糖、餐后2h血糖较对照组有改善(P<0.05);两组酶学及肌酐变化未见明显差异。结论依折麦布能有效改善糖尿病患者的血脂谱、改善空腹血糖及餐后2h血糖水平,降低(hs-CRP),且安全性良好。
Objective To evaluate the efficacy and safety of ezetimibe in diabetic patients with hypercholesterolemia. Methods 58 cases of clinically diagnosed patients with diabetes mellitus and hypercholesterolemia were randomly divided into treatment group (ezetimibe combined with simvastatin) and control group (simvastatin commonly used), the treatment course was 12 weeks, two Fasting blood glucose, 2h postprandial blood glucose, total cholesterol, low density lipoprotein cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), serum creatinine (Scr), creatine kinase, alanine aminotransferase, Aspartate aminotransferase. Results Both LDL-C and LDL-C levels in both groups were significantly lower than those in the control group (P <0.05), and the treatment group was significantly higher than the control group (P <0.01) There was no significant difference in enzyme and creatinine group. Conclusion Ezetimibe can effectively improve the blood lipid profile of diabetic patients, improve fasting blood glucose and postprandial blood glucose levels 2h, reduce (hs-CRP), and good safety.